Sun Pharmaceutical Industries’ earnings call for the fourth quarter of fiscal 2020 provided a glimpse of the challenging environment that the Indian firm, like the rest of the industry, was operating in amid COVID-19, both on home turf and in the US.
While a significant proportion of physicians stayed away from their clinics in India and sales personnel were initially grounded amid...




